Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 11—November 2008


Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany

Barbara Eker, Johannes Ortmann, Giovanni B. Migliori, Giovanni Sotgiu, Ralf Muetterlein, Rosella Centis, Harald Hoffmann, Detlef Kirsten, Tom Schaberg, Sabine Ruesch-Gerdes, Christoph LangeComments to Author , and for the German TBNET Group
Author affiliations: Research Center Borstel, Borstel, Germany (B. Eker, S. Ruesch-Gerdes, C. Lange); Karl-Hansen-Clinic, Bad Lippspringe, Germany (J. Ortmann); World Health Organization Collaborating Center for TB and Lung Diseases, Tradate, Italy (G.B. Migliori, R. Centis); Sassari University, Sassari, Italy (G. Sotgiu); Regional Hospital, Pasberg, Germany (R. Muetterlein); Asklepios-Hospital, Gauting, Germany (H. Hoffmann); Hospital Großhansdorf, Großhansdorf, Germany (D. Kirsten); Deakoness Hospital, Rotenburg, Germany (T. Schaberg);

Main Article

Table 2

Logistic regression analysis of the association of treatment failure (death and failure) with potential explanatory factors*

Variables Crude OR (95% CI) Adjusted OR (95% CI)
Male gender 4.46 (0.56–35.5) 5.8 (0.61–56.6)
Age, y 1.05 (1.01–1.09) 1.06 (1.01–1.1)
Immigrant status 1.18 (0.13–10.2) 0.7 (0.07–6.6)
HIV seropositivity 5 (0.76–32.6) 2.5 (0.28–22.1)
Previous TB treatment >30 d 0.7 (0.26–2.2) 0.4 (0.11–1.3)
Streptomycin resistance 1.35 (0.15–11.4) 1.18 (0.13–10.69)
Ethambutol resistance 1.74 (0.52–5.7) 0.99 (0.29–3.3)
Pyrazinamide resistance 1.65 (0.57–4.7) 1.08 (0.35–3.3)
Fluoroquinolone resistance 1.67 (0.32–8.6) 0.86 (0.09–7.7)
Resistance to injectable second-line drugs 1.16 (0.3–4.5) 1.28 (0.31–5.2)
Resistance to all second-line drugs 1.18 (0.34–3.9) 1.35 (0.37–4.8)

*OR, odds ratio; CI, confidence interval; TB, tuberculosis.

Main Article

1Additional German Tuberculosis Network European Trials group (TBNET) contributors: R. Eberhardt, Thorax-Clinic-Heidelberg, Heidelberg; A. Esselmann, Pulmonary Clinic, Hemer; H. Flick, Charité, Berlin; M. Hamm, Hospital Diekholzen, Diekholzen; P. Hammerl, Hospital Immenhausen, Immenhausen; H. Hang, Hospital Schillerhöhe, Schillerhöhe; P. Hannemann, Deakoness Hospital, Neustadt; D. Hillemann, Research Center Borstel, Borstel; B. Kretz, Asklepios Hospital, Gauting; C. Laumanns, Bethania Hospital, Solingen; G. Liebetrau, Lostau Hospital, Lostau; S. Ott, Helios Clinic Emil von Behring, Berlin; A. Paulick, Pulmonary Clinic-Coswig, Coswig; M.W. Pletz, Hannover Medical School, Hannover; M. Rau, Pulmonary Clinic, Wangen; G. Rohde, Bergmannsheil Hospital, Bochum; A. de Roux, Evangelische Lungenklinik, Berlin; C. Schaudt, Hospital St. Blasien, St. Blasien; K-D.Schneider, Pulmonary Clinic, Hannover-East, Hannover; S. Stenger, University Hospital, Ulm; D. Wagner, University Hospital, Freiburg; and T. Wolf, University Hospital, Frankfurt.